Title
Uticaj genske varijabilnosti P-glikoproteina i citohroma P450 na farmokokinetiku klopidogrela kod bolesnika sa akutnim koronarnim sindromom
Creator
Stokanović, Dragana S. 1980-
Copyright date
2016
Object Links
Select license
Autorstvo-Nekomercijalno-Bez prerade 3.0 Srbija (CC BY-NC-ND 3.0)
License description
Dozvoljavate samo preuzimanje i distribuciju dela, ako/dok se pravilno naznačava ime autora, bez ikakvih promena dela i bez prava komercijalnog korišćenja dela. Ova licenca je najstroža CC licenca. Osnovni opis Licence: http://creativecommons.org/licenses/by-nc-nd/3.0/rs/deed.sr_LATN. Sadržaj ugovora u celini: http://creativecommons.org/licenses/by-nc-nd/3.0/rs/legalcode.sr-Latn
Language
Serbian
Cobiss-ID
Theses Type
Doktorska disertacija
description
Datum odbrane: 08.07.2016.
Other responsibilities
mentor
Jevtović-Stoimenov, Tatjana
član komisije
Jović, Zorica
član komisije
Pešić, Srđan
član komisije
Apostolović, Svetlana
član komisije
Janković, Slobodan 1961-
Academic Expertise
Medicinske nauke
University
Univerzitet u Nišu
Faculty
Medicinski fakultet
Group
Katedra za farmaciju
Alternative title
The effect of P-glycoprotein and cytocrome P450 genetic variabilitz on clopidogrel pharmacokinetics in patients with acute coronary syndrome
Publisher
[D. S. Stokanović]
Format
153 str.
description
Biografija: str. 153
description
Pharmacology
Abstract (en)
Clopidogrel is an antiplаtelet agent prescribed in patients with acute coronary syndrome. As a prodrug, it is being absorbed in small intestinum, which is affected by the activity of P-glycoprotein. Its metabolic transformation towards the active metabolite has two phases, with 2-oxo-clopidogrel as an intermediary metabolite, involвing numerous cytochrome P450 enzymes.
The study was performed on patients with acute coronary syndrome. Using ultrahigh performance liquid chromatography with tandem mass spectrometry (UHPLC-MS/MS), concentrations of clopidogrel and 2-oxo-clopidogrel were measured in patients’ plasma. Pharmacogenetic testing included the determination of P-glycoprotein (ABCB1 C3435Т) and cytochrome P450 polymorphisms (CYP2C19*2, CYP2C19*17 and CYP2C9*2). Using statistical and population pharmacokinetic analysis methods, we aimed to determine the effect of genetic variability on clopidogrel pharmacokinetics, as well of the other clinical factors and co-medication.
Our results show that patients with ABCB1 3435TT genotype achieve lower concentrations of clopidogrel and 2-oxo-clopidogrel in plasma, in comparison with the carriers of at least one wild-type allele. Genetic variability of CYP2C19 and CYP2C9 had no significance for clopidogrel pharmacokinetics. The model of clopidogrel clearance, developed by population pharmacokinetic analysis, pointed out alanine aminotranspherase, clopidogrel daily dose, total body mass and co-medication with pantoprazole, as significant covariates. Other factors that may be significant, and whose role in clopidogrel pharmacokinetics was proven in this study, were: age, gender, body height, left ventricle ejection fraction, heart rate, lipid status, diabetes mellitus type 2, as well as co-medication with ACE-inhibitors, beta-blockers, amlodipine and trimetazidine.
As a conclusion, it can be stated that P-glycoprotein genetic variability is significantly involved in clopidogrel pharmacokinetics, which further affects the platelet aggregation inhibition and the patients’ clinical course. Besides, while prescribing antiplatelet therapy in patients with acute coronary syndrome, numerous other factors and the possibility of interactions, should be taken into account.
Authors Key words
klopidogrel, 2-okso-klopidogrel, farmakokinetika, farmakogenetika, P-glikoprotein, citohrom P450 enzim, CYP2C19, CYP2C9, akutni koronarni sindrom
Authors Key words
clopidogrel, 2-oxo-clopidogrel, pharmacokinetics, pharmacogenetics, P-glycoprotein, cytochrome P450 enzymes, CYP2C19, CYP2C9, acute coronary syndrome
Classification
615.22.015:575]:616.12(043.3)
Subject
B 740
Type
Elektronska teza
Abstract (en)
Clopidogrel is an antiplаtelet agent prescribed in patients with acute coronary syndrome. As a prodrug, it is being absorbed in small intestinum, which is affected by the activity of P-glycoprotein. Its metabolic transformation towards the active metabolite has two phases, with 2-oxo-clopidogrel as an intermediary metabolite, involвing numerous cytochrome P450 enzymes.
The study was performed on patients with acute coronary syndrome. Using ultrahigh performance liquid chromatography with tandem mass spectrometry (UHPLC-MS/MS), concentrations of clopidogrel and 2-oxo-clopidogrel were measured in patients’ plasma. Pharmacogenetic testing included the determination of P-glycoprotein (ABCB1 C3435Т) and cytochrome P450 polymorphisms (CYP2C19*2, CYP2C19*17 and CYP2C9*2). Using statistical and population pharmacokinetic analysis methods, we aimed to determine the effect of genetic variability on clopidogrel pharmacokinetics, as well of the other clinical factors and co-medication.
Our results show that patients with ABCB1 3435TT genotype achieve lower concentrations of clopidogrel and 2-oxo-clopidogrel in plasma, in comparison with the carriers of at least one wild-type allele. Genetic variability of CYP2C19 and CYP2C9 had no significance for clopidogrel pharmacokinetics. The model of clopidogrel clearance, developed by population pharmacokinetic analysis, pointed out alanine aminotranspherase, clopidogrel daily dose, total body mass and co-medication with pantoprazole, as significant covariates. Other factors that may be significant, and whose role in clopidogrel pharmacokinetics was proven in this study, were: age, gender, body height, left ventricle ejection fraction, heart rate, lipid status, diabetes mellitus type 2, as well as co-medication with ACE-inhibitors, beta-blockers, amlodipine and trimetazidine.
As a conclusion, it can be stated that P-glycoprotein genetic variability is significantly involved in clopidogrel pharmacokinetics, which further affects the platelet aggregation inhibition and the patients’ clinical course. Besides, while prescribing antiplatelet therapy in patients with acute coronary syndrome, numerous other factors and the possibility of interactions, should be taken into account.
“Data exchange” service offers individual users metadata transfer in several different formats. Citation formats are offered for transfers in texts as for the transfer into internet pages. Citation formats include permanent links that guarantee access to cited sources. For use are commonly structured metadata schemes : Dublin Core xml and ETUB-MS xml, local adaptation of international ETD-MS scheme intended for use in academic documents.